The University of Texas MD Anderson Cancer Center, Houston, TX
Spyridon P Basourakos , John W. Davis , Brian Francis Chapin , John Francis Ward , Curtis Alvin Pettaway , Louis L. Pisters , Mary F. Achim , Xuemei Wang , Seungtaek Choi , Deborah A. Kuban , Patricia Troncoso , Christopher Logothetis , Timothy C. Thompson , Jeri Kim
Background: Given the morbidities of and limited tumor tissue from prostate biopsies (BXs), circulating biomarkers distinguishing indolent from aggressive disease and predicting disease reclassification (DR) could transform early prostate cancer (PC) management. We have shown that caveolin-1 (Cav-1), a component of caveolae and cellular membrane, is secreted by PC cells, and implicated in the transition from high grade prostatic epithelial neoplasia to prostate cancer and associated with biochemical recurrence after prostatectomy. We evaluated Cav-1’s potential to predict DR during active surveillance (AS). Methods: In a single-institution prospective study, between 2006 and 2014, 825 patients (pts) with early PC were stratified to AS group (GR) I (favorable risk: Gleason score [GS]/single core of 3+3/ < 3 mm or 3+4/ < 2 mm and PSA < 4 ng/mL), II (pt choice), or III (comorbidities preventing local therapy). Pts had entry BX within 6 months of diagnostic BX and repeat BXs every 1–2 years. Tumor volume (TV) or grade increases prompted DR. PSA was measured every 6 months. Baseline plasma Cav-1 was measured in 542 pts using established ELISA in GR I and II pts. Univariate and multivariate logistic regression analyses assessed associations between patient clinicopathologic characteristics and DR. Results: Of 542 pts, 190 (35.1%) met GR I criteria; 352 (64.9%) met GR II criteria. Median age was 64 years; clinical stage cT1c was found in 88.6%; median PSA was 4.1 ng/mL; and GS was 3+3 in 87.3%. After a median of 3.1 years’ follow-up, 163 (30.1%) had met DR. Mean and median Cav-1 levels were 2.2 (SD, 8.5) ng/mL and 0.2 (range, 0, 85.5) ng/mL, respectively. By univariate analysis, log-transformed Cav-1 was a significant predictor for DR (p= .01; OR = 1.33). No association between Cav-1 and PSA or Cav-1 and testosterone was found. On multivariate analysis, adjusting for age, PSA, TV, and GR assignment, log-transformed Cav-1 remained significantly associated with DR (p= .04; OR = 1.27). Longitudinal Cav-1 plasma levels and tissue expression are under study. Conclusions: In a prospective AS cohort, plasma Cav-1 predicted DR independent of other parameters. If validated, results may refine patient selection for AS. Clinical trial information: NCT00490763
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Takuma Kato
2023 ASCO Genitourinary Cancers Symposium
First Author: Mary Fakunle
2021 Genitourinary Cancers Symposium
First Author: Takuma Kato
2024 ASCO Genitourinary Cancers Symposium
First Author: Ekamjit Singh Deol